A
Alessandra Mosca
Researcher at University of Eastern Piedmont
Publications - 63
Citations - 2326
Alessandra Mosca is an academic researcher from University of Eastern Piedmont. The author has contributed to research in topics: Prostate cancer & Renal cell carcinoma. The author has an hindex of 17, co-authored 55 publications receiving 1787 citations. Previous affiliations of Alessandra Mosca include Sapienza University of Rome & University of Turin.
Papers
More filters
Journal ArticleDOI
Targeting PI3K/Akt/mTOR Signaling in Cancer.
TL;DR: The present status of the development of specific PI3K, Akt, and mTOR inhibitors, from already registered medicines to novel compounds that are just leaving the laboratory bench are addressed.
Journal ArticleDOI
Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease
Alfredo Berruti,Alessandra Mosca,Marcello Tucci,Carlo Terrone,Mirella Torta,Roberto Tarabuzzi,Lucianna Russo,Cecilia Maria Cracco,Enrico Bollito,Roberto Mario Scarpa,Alberto Angeli,Luigi Dogliotti +11 more
TL;DR: Elevated plasma CgA levels are frequently observed in prostate cancer patients with hormone-refractory disease and correlate with poor prognosis, and their prognostic role was evaluated together with patient performance status, Gleason score and the presence of visceral metastases.
Journal ArticleDOI
Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease.
Alfredo Berruti,Alessandra Mosca,Francesco Porpiglia,Enrico Bollito,Marcello Tucci,F. Vana,Cecilia Maria Cracco,Mirella Torta,Lucianna Russo,Susanna Cappia,Andrea Saini,Alberto Angeli,Mauro Papotti,Roberto Mario Scarpa,Luigi Dogliotti +14 more
TL;DR: Chromogranin A expression in prostate cancer biopsies is an independent predictive factor of hormone refractory disease in patients with newly diagnosed prostate cancer on early androgen deprivation therapy and plasma chromogranIn A is also a reliable predictive marker and the predictive significance is maintained over time.
Journal ArticleDOI
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis
Sergio Bracarda,Roberto Iacovelli,Luca Boni,Mino Rizzo,Lisa Derosa,Matteo Rossi,Laura Galli,G. Procopio,Michele Sisani,Flavia Longo,Matteo Santoni,Franco Morelli,G. Di Lorenzo,A. Altavilla,C. Porta,Andrea Camerini,Bernard Escudier,Angelo Martignetti,Riccardo Ricotta,Donatello Gasparro,Roberto Sabbatini,Giovanni Luca Ceresoli,Alessandra Mosca,Daniele Santini,Claudia Caserta,Luigi Cavanna,Francesco Massari,Teodoro Sava,Corrado Boni,Elena Verzoni,Giacomo Cartenì,Alketa Hamzaj +31 more
TL;DR: Sunitinib is recommended in metastatic renal cell carcinoma (mRCC) as mentioned in this paper, but it is frequently associated with relevant toxicities and subsequent dose reductions, thus, alternative schedules, such as 2-week on treatment and 1-week off (2/1 schedule), might improve tolerability.
Journal ArticleDOI
Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma.
E. Bollito,Alfredo Berruti,M. Bellina,Alessandra Mosca,E. Leonardo,R. Tarabuzzi,S. Cappia,M. Mari,Marco Tampellini,Dario Fontana,Luciano Gubetta,Alberto Angeli,Luigi Dogliotti +12 more
TL;DR: Data support the concept that NE differentiation in human prostate cancer has a negative prognostic significance and Circulating CgA levels reflect immunohistochemical findings.